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Abstract
Background: The molecular mechanism initiating deep pressure ulcer remains to be elucidated. The present study
tested the hypothesis that the ubiquitin proteasome system is involved in the signalling mechanism in pressure-
induced deep tissue injury.
Methods: Adult Sprague Dawley rats were subjected to an experimental compression model to induce deep
tissue injury. The tibialis region of the right hind limb was subjected to 100 mmHg of static pressure for six hours
on each of two consecutive days. The compression pressure was continuously monitored by a three-axial force
transducer within the compression indentor. The left hind limb served as the intra-animal control. Muscle tissues
underneath the compressed region were collected and used for analyses.
Results: Our results demonstrated that the activity of 20S proteasome and the protein abundance of ubiquitin and
MAFbx/atrogin-1 were elevated in conjunction with pathohistological changes in the compressed muscle, as
compared to control muscle. The administration of the proteasome inhibitor MG132 was found to be effective in
ameliorating the development of pathological histology in compressed muscle. Furthermore, 20S proteasome
activity and protein content of ubiquitin and MAFbx/atrogin-1 showed no apparent increase in the MG132-treated
muscle following compression.
Conclusion: Our data suggest that the ubiquitin proteasome system may play a role in the pathogenesis of
pressure-induced deep tissue injury.
Background
Pressure ulcer represents a considerable clinical pro-
blem. An estimated one billion dollars is spent annually
to manage pressure ulcers in the United States [1].
A pressure ulcer is defined as localized damage to the
skin and the underlying tissues in response to moderate
but sustained mechanical compression [2]. The exact
cause and pathogenesis of pressure ulcers are largely
unknown. Pressure ulcers are generally categorized into
superficial or deep pressure ulcers. These are distinctly
differentiated based on their developmental processes.
A superficial ulcer is confined to the skin layer, and can
be diagnosed visually at an early stage. In contrast, a
deep ulcer originates in the underlying tissues overlying
a bony prominence in the compressed region, and its
development involves subsequent progression of the
injury upwards until it penetrates to the skin [3]. Deep
ulcer is of considerable clinical concern as the tissue
damage is already very severe by the time the ulceration
becomes visible and detectable at the cutaneous layer.
This makes the prognosis very uncertain and hinders
therapeutic follow-up. To better characterize this serious
form of pressure ulcer, the term “deep tissue injury” has
been introduced by the US National Pressure Ulcer
Advisory Panel (NPUAP) in order to emphasize that
deep pressure ulcer occurs as “a pressure-related injury
to subcutaneous tissues under intact skin” [4-9].
Ubiquitin proteasome system is a non-lysosomal cellu-
lar process responsible for the housekeeping functions
of the regulation of protein turnover and the elimination
of abnormal proteins in eukaryotic cells. This system has
been shown to be involved in the regulation of
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important biological events including cell division, stress
response [10], signalling transduction [11,12], transcrip-
tion, and protein sorting [13]. Ubiquitin proteasome sys-
tem could probably be one of the potential candidates
of the molecular target responsible for the pathogenesis
of pressure ulcer. In particular, the ubiquitin proteasome
system signalling has been shown to be critical for coor-
dinating muscle degradation [14]. In this pathway, pro-
teins tagged with a polyubiquitin signal are degraded by
a proteasome complex. Ubiquitination is the process of
the covalent attachment of ubiquitin to a protein sub-
strate. The formation of a polyubiquitin chain essentially
relies on the E3 ligases which function to selectively
recognize their specific protein substrates [15]. Muscle
specific E3 ubiquitin ligases, including muscle atrophy
F-box/atrophy gene-1 (MAFbx/atrogin-1) and muscle
ring finger 1 (MuRF1), have been previously identified
[16,17]. MAFbx/atrogin-1 contains an F-box domain
which is a characteristic motif found in the SCF (Skp1,
cdc53/cullin and F-box protein) subfamily of E3 ubiqui-
tin ligases. The F-box functions to link the elements of
the E3 complex to the targeted protein [15,18]. MuRF1
belongs to the RING Finger E3 ligase subfamily which
was initially found in association with the myofibril
[18,19]. These two muscle-specific E3 ligases have been
demonstrated to be upregulated in muscle degradation
due to disuse and to catabolic conditions. They are gen-
erally considered as the critical regulatory components
of the ubiquitin-proteasome system mediated catabolic
process [2,14,15,20].
Research has resulted in some but limited understand-
ing of the etiology of pressure ulcer. The identified criti-
cal risk factors include shear, moisture, friction,
malnutrition, and pressure [21,22]. Yet, the fundamental
knowledge of the pathology of deep pressure ulcer is
still missing. The cellular signalling events coordinating
deep tissue injury need to be revealed so that novel pre-
ventive and treatment regimens can be developed. Dri-
ven by the fact that skeletal muscle tissue is particularly
sensitive to prolonged compression [23-26] and the
destructive nature of the ubiquitin proteasome system in
muscle [18,27,28], the present study investigated
whether the muscle ubiquitin proteasome system is
involved in the underlying mechanism of the pathology
of deep pressure ulcer. We tested the hypothesis that
the muscle ubiquitin proteasome system plays a causa-
tive role in pressure-induced deep tissue injury. As the
pathogenesis of deep pressure ulcer might involve the
hypoxia- and cellular deformation-related mechanisms,
the gene expression levels of molecular markers of
hypoxia and cellular chaperone including hypoxia indu-
cible factor (HIF-1a) and heat shock protein70 (HSP70)
were also investigated in this study.
Methods
Animals
Female adult Sprague Dawley rats weighing about 300 g
were used in this study. The animals were kept in con-
ventional housing under pathogen-free conditions,
exposed to a reverse light condition of 12:12-hours
light-dark, and fed with standard nutrient diet and water
ad libitum. Animal research ethics approval was
obtained from the Animal Ethics Sub-committee of The
Hong Kong Polytechnic University. The animal care
standards were followed by adhering to the recommen-
dations for the care of laboratory animals as advocated
by the American Association for Accreditation of
Laboratory Animal Care (AAALAC) and following the
policies and procedures detailed in the Guide for the
Care and Use of Laboratory Animals as published by
the U.S. Dept. of Health and Human Services and pro-
claimed in the Animals Welfare Act.
Muscle Compression Procedure
After acclimatization with the housing environment, rats
(N = 8) were subjected to an in vivo pressure-induced
deep tissue injury protocol, previously established in the
same laboratory, with minor modifications [29-31].
Briefly, animals were first anesthetized with ketamine (80
mg/kg) and xylazine (8 mg/kg) by intra-peritoneal (i.p.)
injection. One third of the initial dose was i.p. adminis-
tered approximately one to two times throughout the
compression procedure to maintain the level of anaesthe-
sia. Anesthetization was assured by testing the loss of
reflex action and moustache dithering test. The hind
limbs were shaved with an electronic razor before being
subjected to compression, which involved moderate pro-
longed compression loading with a static pressure of 100
mmHg. This was applied to an area of 1.5 cm2 over the
tibialis region of the right limb. The loading duration was
six hours on each of two consecutive days. The compres-
sion force was continuously monitored by a three-axial
force transducer within the compression indentor. A
laser Doppler flowmetry (DRT4, Moor Instruments,
Axminster, UK) with a contact probe (DP1T/7-V2) was
used to monitor the blood flow of the compression site
as previously described [29]. The left uncompressed limb
served as intra-animal control. Rats were killed by over-
dose of ketamine and xylazine twenty hours after the last
session of compression. Tissue samples were excised
from the area directly underneath the indentor region,
frozen in liquid nitrogen-cooled isopentane and stored at
-80°C until further analysis. To examine the MAFbx/
atrogin-1 protein expression in muscle immediately after
the compression protocol, muscle samples of the rats
that were sacrificed immediately after two sessions of
6-hours of compression over two consecutive days
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(2D-IM group) [31] were used to perform Western blot
analysis of MAFbx/atrogin-1.
Administration of Proteasome Inhibitor
Rats were randomly divided into two groups to receive
either MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leuc-
inal, Z-LLL-CHO) or DMSO (vehicle control) adminis-
tration (N = 5 per group). MG132, a cell-permeable
peptide aldehyde that inhibits the major peptidase activ-
ities of proteasome [32] was purchased from Merck and
dissolved in DMSO for use. A dose of 10 mg/kg of
MG132 that has been used in previous studies was
adopted in this study [33,34]. The MG132 administra-
tion was carried out by two intraperitoneal injections of
5 mg/kg of MG132 right before each of the two 6-hours
compression sessions. Equal volumes of DMSO were
administered to the control animals.
Histological Analysis
Standard hematoxylin and eosin staining procedure was
used to examine the histology of tissues. Ten micro-
meters thick cross-sections were prepared from frozen
muscle tissue samples in a cryostat at -20°C. The sec-
tions were air dried at room temperature and fixed with
10% formalin solution (HT-5011, Sigma Aldrich). Sam-
ples were stained with Mayer’s hematoxylin (MHS-1,
Sigma Aldrich) and 1% eosin in CaCl2 (318906, Sigma
Aldrich) following a series of alcohol-mediated dehydra-
tion steps, and stained sections were mounted in clarion
mounting medium (C-0487, Sigma Aldrich).
Real time Quantitative PCR Analysis
Total RNA was extracted from frozen compressed and con-
trol muscle samples with TriReagent (Molecular Research
Center) based on the guanidine thiocynate method. Muscle
samples were homogenized mechanically in ice-cold TriR-
eagent. The extracted total RNA was solubilized in RNase-
free H2O and quantified by spectrophotometry at l = 260
nm and the purity of RNA was confirmed by examining the
260/280 ratio. Superscript III reverse transcriptase kit (Invi-
trogen Life Technology) was used to generate complemen-
tary DNA (cDNA). Reverse transcription was performed by
following the manufacturer’s recommendations, with a
reaction volume of 20 μl which included 1 μg of total RNA,
decamer primers and superscript reverse transcriptase. For
the cDNA prepared from the preliminary samples collected
from the rats which had not been treated with DMSO or
MG132, the PCR reaction was performed in TaqMan Mas-
ter Mix, primer and Taqman probes, and RNase and
DNase free water on an ABI7500 real time PCR thermocy-
cler (Applied Biosystems). Primers and probes for the Taq-
Man assay were designed specifically against the sequence
of rat MAFbx/atrogin-1, MuRF1, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) by the manufacturer
[MAFbx/atrogin-1: NM_133521.1 (GenBank accession
number), Rn00591730_m1 (Applied Biosystems TaqMan
assay ID), 61 bp (Amplicon length); MuRF-1: NM_
080903.1, Rn00590197_m1, 56 bp; GAPDH: NM_017008.3,
Rn99999916_s1, 87 bp]. For the TaqMan PCR, GAPDH
was used as internal control and the relative quantification
of gene expression was calculated using the comparative
threshold cycle ΔΔCT method [35]. For the cDNA prepared
from the samples collected from the rats which had been
treated with DMSO or MG132, the PCR reaction was per-
formed in SYBR green/ROX qPCR Master Mix (Fermentas)
with forward and reverse primers for ubiquitin, MAFbx/
atrogin-1, HIF-1a, HSP70 or b2 microglobulin (b2M)
(Table 1), and RNase/DNase-free water in ABI7500 real
time PCR thermocycler (Applied Biosystems). For the
SYBR green/ROX-mediated PCR, b2M was included as
internal housekeeping control gene. A relative standard
curve (concentration vs. threshold cycle) of target and
reference genes for quantification of PCR products was
generated by dilution of cDNA from the calibrator. Com-
plementary DNA prepared from uncompressed control
samples was used as the calibrator to generate the stan-
dard curve. Results were expressed as the concentration
ratio of the target gene to b2M of each sample. All PCR
amplification and sequences were verified and the thresh-
old for kinetic detection was set to occur over linear
amplifications over several ranges of primers and RNA
levels. The amplification efficiency for the PCR reactions
was assessed by including serially diluted cDNAs with
known DNA concentrations as positive control. All sam-
ples were run in duplicate, with control and compressed
samples run on the same plate.
Table 1 Primer Used in Real Time RT-PCR Analysis
Gene Accession
Number
Primers
(F; forward primer, R; reverse
primer)
Ubiquitin NM017314 F: 5’GGGCATGCAGATCTTTGTGAA3’
R: 5’ACCTCCAGGGTGATGGTCTTG3’
MAFbx/
atrogin-1
NM133521 F:
5’TGAAGACCGGCTACTGTGGAAGAGAC3’
R:
5’TTGGGGTGAAAGTGAGACGGAGCAG3’
HIF-1a NM024359 F:
5’AACAAACAGAATCTGTCCTCAAACC3’
R: 5’CAGGTAATGGAGACATTGCCAG3’
HSP70-1 X77207 F: 5’CGAGGGCATCGACTTCTACACG3’
R: 5’ATCTGCGCCTTGTCCAGCTTG3’
HSP70-2 X77208 F: 5’CTCGTCCATGGTGCTGACCAAG3’
R: 5’CCGCTGCGAGTCGTTGAAGTAG3’
HSP70-3 X77209 F: 5’AGGACTCAACGTGCTGCGAATC3’
R: 5’TCAGGATGGACACGTCGAACG3’
b2M NM012512 F: 5’CGTGATCTTTCTGGTGCTTGTC3’
R: 5’TTCTGAATGGCAAGCACGAC3’
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Proteasome Activity Assay
The proteasome enzymatic activity was measured by
using a proteasome 20S assay kit (Enzo Life Sciences)
following the manufacturer’s instructions. In brief, the
protein extract from muscle tissue was used to perform
assessment of proteasome 20S activity by measuring the
hydrolysis of a fluorogenic peptidyl substrate Suc-Leu-
Leu-Val-Tyr-AMC (AMC: 7-amino-4-methylcoumarin)
following the 0.03% sodium dodecyl sulphate-activation
step. This substrate was cleaved by the proteasome
activity and the subsequently released free AMC was
then detected by a fluorimeter with an excitation wave-
length of 380 nm and emission wavelength of 460 nm.
The fluorescence signal was monitored before and after
one-hour incubation at 37°C. The change in fluores-
cence signal was normalized to the amount of protein
used in the assay.
Immunocytochemical Analysis
Frozen tissue cross-sections were cut to a thickness of
10 μm in a cryostat at -20°C. The sections were air
dried at room temperature and fixed with 10% formalin
solution (Sigma Aldrich). Background activity was
minimized by blocking the section with 5% goat serum.
After washing, sections were incubated with anti-ubiqui-
tin mouse monoclonal (3936, Cell Signaling), anti--
MAFbx rabbit polyclonal (sc-33782, Santa Cruz
Biotechnology) or anti-MuRF1 rabbit polyclonal
(sc-32920, Santa Cruz Biotechnology) antibodies.
Sections were then processed by using Vectastain Elite
ABC Peroxidase kit (PK6100, Vector Laboratories) with
ImmPACT DAB peroxidase substrate (SK4105, Vector
Laboratories) or exposed to anti-rabbit IgG (H+L) fluor-
escein-conjugated secondary antibody (FI-1000, Vector
Laboratories). Negative controls were performed by
eliminating the primary or secondary antibody. Sections
were examined under a Nikon 80i microscope. Images
were captured with a Nikon DXM 1200C camera using
Nikon ACT-1C software.
Western Blot Analysis
Protein abundance of ubiquitin and MAFbx/atrogin-1
was measured in the compressed and control muscles.
Soluble protein was extracted from muscle samples by
the following procedure. After mincing and homogeni-
zation in ice-cold lysis buffer (10 mM NaCl, 1.5 mM
MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 0.1% Tri-
ton X-100, and 1 mM dithiothreitol), muscle homoge-
nate underwent serial centrifugations. Protease inhibitor
cocktail (P8340, Sigma-Aldrich) was added to the
extracted protein followed by spectrophotometric mea-
surement of protein concentration at 595 nm using a
commercial Bradford method (Coomassie Protein Assay,
Pierce). The protein concentration was determined in
duplicate by following the manufacturer’s recommenda-
tions with bovine serum albumin (BSA) used as stan-
dard. Protein extracts were then boiled at 95°C for 5
min in Laemmli buffer with 5% b-mercaptoethanol.
Forty μg of protein was loaded on a 10% polyacrylamide
gel. After electrophoretic separation by SDS-PAGE, the
proteins were transferred to polyvinylidene difluoride
(PVDF) membranes (Immobilon P, Millipore). The
membranes were blocked in 5% nonfat milk in Tris-buf-
fered saline with 0.1% Tween 20 (TBST) for 1 h at
room temperature after the transfer, and incubated
overnight at 4°C with corresponding primary antibody:
anti-ubiquitin mouse monoclonal antibody (1:1000 dilu-
tion, 3936, Cell Signaling) or anti-MAFbx/atrogin-1 rab-
bit polyclonal antibody (1:200 dilution, sc33782, Santa
Cruz) diluted in TBST with 2% bovine serum albumin
(BSA). Membranes were then washed in TBST and
incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies at room temperature for
1 h (1:3000 dilution, 7076 for anti-mouse antibody, 7074
for anti-rabbit antibody, Cell Signaling). Luminol reagent
(NEL103001EA, Perkin Elmer) for chemiluminescent
detection of HRP was then applied. The chemilumines-
cent signal was captured with a Kodak 4000R Pro cam-
era. The resulting bands were quantified as optical
density (OD) x band area and expressed as arbitrary
units. b-tubulin (1:2000 dilution, T0198, Sigma Aldrich)
was probed and used as the reference of internal control.
Data on ubiquitin and MAFbx/atrogin-1 were expressed
by normalizing to the signal of b-tubulin.
TUNEL Analysis
DNA strand breaks were assessed by fluorescent labelling
of terminal dUTP nick end labelling (TUNEL) using a
detection kit according to the manufacturer’s instructions
(11684795910, Roche Applied Science). In brief, 10 μm
thick frozen sections were cut in a freezing cryostat at -20°
C. Tissue sections were air dried at room temperature,
fixed with 4% paraformaldehyde in PBS, permeabilized
with 0.2% Triton X-100 in 0.1% sodium citrate, and incu-
bated with the fluorescein-conjugated TUNEL reaction
mixture. A section treated with DNase I was examined as
positive control. Omission of the addition TdT enzyme in
the TUNEL reaction mixture was included as negative con-
trol. The sections were then mounted with DAPI mounting
medium to visualize nuclei (Vectashield mounting med-
ium, Vector Laboratories). TUNEL- and DAPI-stained
nuclei were examined under a fluorescence microscope
(Biological Research Microscope 80i, Nikon) equipped with
a digital camera (DXM 1200c, Nikon) using Nikon ACT-
1C software. SPOT RT software (Diagnostic Instruments)
was then used to stack and analyse the images.
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Statistical Analysis
All data are presented as mean ± standard error of
mean. One-way ANOVA with Tukey HSD post hoc test
was used to examine differences between groups. Level
of statistical significance was set at p < 0.05.
Results
Compression induced muscle pathohistology and increase
in MAFbx/atrogin-1 protein expression
Preliminary experiments were conducted in rats which
had not been treated with DMSO or MG132 to demon-
strate the potential involvement of the ubiquitin protea-
some system in compression-induced muscle pathology.
Gross muscle histology and expression of ubiquitin E3
ligases, MAFbx/atrogin-1 and MuRF1 were examined.
Histological analysis demonstrated the presence of
pathological muscle changes following compression
(Figure 1 A and 1B). These included loss of angular
shape and rounding contour of cross-sectional muscle
fibres, increase in nuclei number in the interstitial space,
increased proportion of interstitial space, and internali-
zation of peripherally located nuclei in muscle cells
(Figure 1 B). These pathohistological characteristics
were noticeably in contrast to the normal histology of
muscle cells in uncompressed samples which showed
tightly packed muscle fibres with polygonal shape and
peripherally located nuclei (Figure 1 A). According to
our fluorescent immunocytochemical analysis, immu-
noreactivity of MuRF1 was found to be unchanged in
muscle in response to compression. However, immunor-
eactivity of MAFbx/atrogin-1 localized in the cytoplas-
mic region of the compressed muscle was apparently
increased when compared to uncompressed muscle (Fig-
ure 1 C and 1D). The mRNA expression of MAFbx/
atrogin-1 and MuRF1 was also examined by real time
quantitative PCR. No significant difference in mRNA
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Figure 1 Compression-induced Pathohistology and Increase in MAFbx/atrogin-1. Preliminary experiments were conducted to expose
untreated rats (neither DMSO nor MG132) to the compression protocol to examine the effect of compression on gross muscle histology and
expression of ubiquitin E3 ligases, MAFbx/atrogin-1 and MuRF1. Gross muscle histology was examined following hematoxylin and eosin staining.
Muscle tissue after compression generally showed pathohistological appearances including rounding shaped muscle cells, accumulated nuclei
number, and internalization of peripherally located nuclei in muscle cells (as shown by arrows in B). Fluorescent immunocytochemical analysis
demonstrated that the protein expression of MAFbx/atrogin-1 was apparently elevated in cytoplasmic region of the compressed muscle (D)
relative to uncompressed muscle (C). No noticeable change in immunoreactivity of MuRF1 was found in the compressed and uncompressed
muscles (data not shown).
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content of MAFbx/atrogin-1 and MuRF1 was observed
with compression treatment.
MG132 treatment alleviated compression-induced muscle
pathohistology
The gross muscle histological changes as induced by
compression in DMSO vehicle-treated rats were similar
to that in the untreated rats. Histological analysis
demonstrated that changes such as loss of tightly packed
polygonal arrangement of muscle cells, round shaped
contour of muscle cells, and increase in nuclei number
were generally observed in compressed muscle of
DMSO-treated animals (Figure 2 upper panels). In con-
trast, these pathohistological appearances were not seen
in the muscle of MG132-treated animals following com-
pression (Figure 2 lower panels).
MG132 treatment precluded compression-induced
elevation of 20S proteasome activity
The 20S proteasome activity in compressed muscle of
DMSO-treated animals was significantly increased by
105% relative to the uncompressed muscle (Figure 3). In
MG132-treated animals, no significant difference was
found in 20S proteasome activity between compressed
and uncompressed muscles (Figure 3).
MG132 treatment precluded compression-induced
increase in ubiquitin and MAFbx/atrogin-1
The protein content of ubiquitin and MAFbx/atrogin-1
was examined by immunocytochemical analysis. Marked
immunopositive staining of ubiquitin was found to be
localized in the cytoplasmic region of scattered muscle
fibres with round contours in the compressed muscle of
DMSO-treated rats whereas no immunoreactivity of ubi-
quitin was detected in uncompressed muscle of DMSO-
rats (Figure 4 upper panels). In contrast, immunoreac-
tivity of ubiquitin was not detected in either uncom-
pressed or compressed muscles of MG132-treated rats
(Figure 4 lower panels). According to our immunocyto-
chemical analysis, MAFbx/atrogin-1 protein abundance
was apparently increased in the compressed muscle rela-
tive to uncompressed muscle of DMSO-rats (Figure 5
upper panels). However, MAFbx/atrogin-1 protein con-
tent was not changed in compressed muscle when com-
pared to uncompressed muscle in MG132-treated rats
(Figure 5 lower panels). MuRF1 protein abundance was
also examined but no apparent change was found in the
compressed muscle relative to uncompressed muscle in
both DMSO- and MG132-treated animals (data not
shown). According to our Western immunoblot analysis,
the protein abundance of ubiquitin was significantly
Uncompressed Compressed
D
M
SO
M
G
13
2
Figure 2 Histological Analysis. Muscle histology was examined following hematoxylin and eosin staining. Histologic appearances indicating
muscle pathology such as loss of tightly packed polygonal muscle cells arrangement, round shaped contour of muscle cells, and increment of
nuclei number were generally observed in compressed muscle of DMSO-treated animals but not MG132-treated animals.
Siu et al. BMC Musculoskeletal Disorders 2011, 12:58
http://www.biomedcentral.com/1471-2474/12/58
Page 6 of 14
increased by 4.8-folds in the compressed muscle when com-
pared to uncompressed muscle of DMSO-treated rats. The
protein abundance of ubiquitin appeared to be increased in
the compressed muscle relative to the uncompressed mus-
cle in MG132-treated rats but this did not reach the
statistical significance level (p > 0.05) (Figure 6). The protein
abundance of MAFbx/atrogin-1 was significantly increased
by 5.2-folds in the compressed muscle when compared to
uncompressed muscle of DMSO-treated animals whereas
no significant difference was found between compressed
and uncompressed muscles in MG132-treated animals (Fig-
ure 6).
MG132 treatment precluded compression-induced
decrease in HSP70-3 mRNA expression
According to our real time PCR analysis, the mRNA
content of ubiquitin and MAFbx/atrogin-1 appeared to
be decreased in the compressed muscle relative to
uncompressed muscle in DMSO- and MG132-treated
animals but these changes did not reach the statistical
significance level (p > 0.05) (Figure 7). No significant
difference was found in the mRNA abundance of HIF-
1a, HSP70-1, and HSP70-2 between the compressed
and uncompressed muscles in DMSO- and MG132-trea-
ted rats (Figure 7). The mRNA abundance of HSP70-3
was significantly decreased by 69% in the compressed
muscle when compared to uncompressed muscle of
DMSO-treated rats whereas no significant difference
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Figure 3 20S Proteasome Activity Assay. 20S proteasome activity
was increased in the compressed muscle of DMSO-treated animals
but not MG132-treated animals. Results were expressed as change
in fluorescence unit normalized to the amount (milligrams) protein
used in the assay. Data are presented as means ± SEM. *p < 0.05
compared with the uncompressed muscle of DMSO-treated animals.
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Figure 4 Immunocytochemical Analysis of Ubiquitin. DAB-mediated immunostaining was used to examine the ubiquitin protein abundance
in uncompressed and compressed muscles of DMSO- and MG132-treated animals. In DMSO-treated rats, uncompressed muscle did not show
any immunoreactivity of ubiquitin whereas compressed muscle demonstrated strong immunoreactivity in the muscle cells (upper panels). The
ubiquitin immunoreactivity was distributed in muscle fibres in a scattered pattern. In MG132-treated rats, no immunoreactivity of ubiquitin was
detected in both uncompressed and compressed muscles (lower panels).
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was found between the compressed and uncompressed
muscles in MG132-treated animals (Figure 7).
MG132 treatment precluded compression-induced
increase in DNA strand breaks
TUNEL-positive nuclei were not detected in the uncom-
pressed muscle of DMSO-treated animals whereas
TUNEL-positive nuclei were observed in the compressed
muscle of DMSO-treated animals. There were no TUNEL-
positive nuclei detected in either the uncompressed or the
compressed muscle of MG132-treated animals (Figure 8).
MAFbx/atrogin-1 protein expression was increased
immediately after compression
According to our Western blot analysis, the protein abun-
dance of MAFbx/atrogin-1 was significantly increased by
96% in the compressed muscle of 2D-IM group (i.e., rats
were sacrificed immediately after two sessions of 6-hours
of compression over two consecutive days) (Figure 9).
Discussion
Pressure-induced deep tissue injury is a severe, life-threa-
tening form of pressure ulcer which causes considerable
health concern because there are no effective treatments.
There is an urgent need to understand the pathology of
deep ulcer in order to identify the molecular targets for
exploring new therapeutic regimens. In this study, our
novel data demonstrated that the ubiquitin proteasome
system is activated as indicated by the elevation of pro-
teasome activity, ubiquitin, and the muscle-specific ubi-
quitin E3 ligase MAFbx/atrogin-1 in an experimental
deep tissue injury protocol. Our data further demon-
strated that proteasome inhibitor MG132 prevented the
compression-induced increases in ubiquitin, MAFbx/
atrogin-1, and 20S proteasome activity, and alleviated the
muscle pathohistology induced by prolonged moderate
compression. These results strongly suggested that the
muscle ubiquitin proteasome system plays a role in the
underlying mechanisms of deep pressure ulcer.
The ubiquitin proteasome system has been shown to
function in the breakdown of muscle [36]. Ubiquitin E3
ligases are essential components in the ubiquitin protea-
some system, and have been demonstrated to be
expressed in increased amounts in catabolic conditions,
during muscle atrophy, metabolic dysregulation, burn
injury, inflammation, eccentric exercise-induced muscle
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Figure 5 Immunocytochemical Analysis of MAFbx/atrogin-1. DAB-mediated immunocytochemistry was used to examine the protein
abundance of MAFbx/atrogin-1 in uncompressed and compressed muscles of DMSO- and MG132-treated animals. Uncompressed muscle of
both DMSO- and MG132-treated rats did not show any immunoreactivity of MAFbx/atrogin-1. Apparent positive immunoreactivity was detected
in the muscle fibres of compressed muscle in only DMSO-treated rats but not in MG132-treated rats.
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damage, alcohol intoxication, and spinal cord injury
[37-43]. The ubiquitin proteasome system signalling has
not been investigated in pressure-induced muscle injury
previously. Our immunocytochemical and biochemical
data presented here illustrate that ubiquitin and MAFbx/
atrogin-1 protein expression and 20S proteasome activity
were elevated in response to sustained moderate compres-
sion. It is worth noting that the expression pattern of
MAFbx/atrogin-1 was localized concurrently with the
inflammation-associated pathohistological appearance such
as the massive accumulation of nuclei in the interstitial
space of muscle tissue. These observations were generally
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consistent with previous findings showing that MAFbx/
atrogin-1 and MuRF1 were induced in response to acute
inflammation as initiated by lipopolysaccharide injection
and sepsis [44]. This strengthens the case that the increase
in the expression of MAFbx/atrogin-1 and ubiquitin is
linked to the proposed role of the ubiquitin proteasome
system in the pathogenesis of deep tissue injury.
Pharmacological inhibition of the ubiquitin proteasome
system using MG132 has been meticulously investigated in
skeletal muscle disorders such as muscle dystrophy. Bonuc-
celli and colleagues have examined the effect of MG132
treatment on the mdx phenotype-related reduction of the
dystrophin and dystrophin-associated proteins expression
in skeletal muscle fibres from mdx mice [45]. By using the
technique of immunofluorescence and Western immuno-
blotting, the administration of MG132, either by local
injection into the muscle or osmotic minipump-mediated
systemic treatment, was demonstrated to effectively rescue
the expression level and sarcolemmal localization of dys-
trophin, b-dystroglycan, a-dystroglycan, and a-sarcoglycan
in gastrocnemius muscle of mdx mice [45]. The histologi-
cal analysis also illustrated the decrease in the extent of
pathological changes in the muscle of mdx mice following
8-days of systemic treatment with MG132 [45]. By using a
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Figure 8 TUNEL Analysis. DNA strand breaks in uncompressed and compressed muscles of DMSO-treated and MG132-treated animals were
assessed by TUNEL assay. TUNEL labelling was stained in green and nuclei were labelled by DAPI staining in blue. TUNEL-positive nuclei were
identified in the images as shown by arrows.
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tissue explant culture model in examining the isolated ske-
letal muscle biopsies, MG132 treatment was further demon-
strated to be successful in restoring the expression of the
protein component of dystrophin-glycoprotein complex
comprising dystrophin, b-dystroglycan, and a-sarcoglycan at
the sarcolemma of muscles from patients with Duchenne
muscular dystrophy (DMD) and Becker muscle dystrophy
(BMD) [46]. Although the nature of myopathy in pressure-
induced deep tissue injury is different from the dystrophin-
deficiency disorders (i.e., patients with DMD/BMD and mdx
mice), the present findings indicated that the inflammation-
associated myopathic histology as induced by sustained com-
pression can also be alleviated by MG132 treatment. These
results were consistent with the reported protective effect of
MG132 in muscle of mdx mice and DMD/BMD patients
[45,46]. A notable finding refers to the alleviation of the
immune cells infiltration in the compressed muscle of the
MG132-treated animals. The mechanism responsible for this
phenomenon is not known. It is speculated that the relation-
ship between the ubiquitin proteasome system and immune
cell signalling (e.g., NF-kappaB activation) might account for
the presently observed phenomenon [11,12]. In support to
the present findings, proteasome inhibitors have been
demonstrated to have anti-inflammatory activities by
blocking the activation of NF-kappaB and by reducing the
production of inflammatory mediators and cytokines [47,48].
Furthermore, the in vivo administration of peptide aldehyde
inhibitor MG132 has been shown to reduce diabetes after
adoptive transfer of autoreactive T cells to nonobese diabetic
mice lacking endogenous T cells and this was probably asso-
ciated with the prevention of T cell proliferation [49]. Their
data also illustrated that MG132 can prevent the prolifera-
tion of BDC2.5 T cells in vitro in a dose-dependent fashion
[49]. Intriguingly, the effects of proteasome inhibitors on
blocking the cell cycle entry of T cells and reducing the
severity of some immune-mediated disorders have been
demonstrated [47,50,51]. Collectively, though the exact
mechanism in explaining the rescuing effect of proteasome
inhibitor in deep pressure ulcer is not known, the present
findings might have clinical implications in the management
of deep pressure ulcer.
An intriguing finding in this study is the prevention of
increased DNA strand breaks as measured by TUNEL
in the MG132-treated muscle following compression.
The relationship of the ubiquitin proteasome system
and the regulation of apoptosis has been generally estab-
lished in non-muscle and muscle cell types [52-54].
However, the inhibition of proteasome has been shown
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to have opposite effects in inducing and suppressing
apoptosis in multiple cell types [52-54]. It has been pos-
tulated that the opposite effects of proteasome inhibition
might be partly attributed to the differentiation status of
the cell types [52-54]. Although the precise association
of proteasome and apoptosis remains to be elucidated,
our findings indicated that compression-induced muscle
pathohistology accompanied by increased DNA frag-
mentation could be alleviated by the administration of
the proteasome inhibitor MG132. Whether the observed
inhibitory effect of MG132 on the compression-induced
elevation of TUNEL-determined DNA fragmentation
might be related to the highly differentiated postmitotic
nature of skeletal muscle remains to be elucidated.
With reference to the results reported by Kwan and
co-workers [29], the present study reproduced the
pathologic histology in muscle tissue by adopting a simi-
lar compression protocol. It is noted that the observed
pathologic characteristics were located in the zone
underneath the indenter and ranged from indenter to
bone as indicated by our histological analysis. It has
been suggested that the tolerance and resistance to
mechanical compression in muscle tissue is lower than
that in soft tissues, such as cutaneous tissue [23-26]. In
agreement with the suggestion that muscle tissue is
more susceptible to pressure-related injury, our data
showed that the pathologic characteristics were exclu-
sively observed in the underlying muscle tissue whereas
no apparent histological indication of injury was found
in the skin layer (data not shown). It is noted that the
present observations are consistent with the previous
findings in the etiology of deep tissue injury using an
animal model with controlled external loading techni-
ques [55,56]. Those findings showed that damage was
incident to the soft tissues in the zone underneath the
indenter and consisted of loss of cross-striation and
infiltration of macrophages [55,56]. It appears that mus-
cle tissues directly enveloping bone surfaces are more
vulnerable to pressure and resulting in pathologic
change probably because of the high concentrated load
and mechanical stress that the muscle needs to bear
with compression. Accompanied by the demonstrated
pathologic role of the ubiquitin proteasome system, the
present study put forward muscle as an important initi-
ating site for deep pressure ulcer. These findings war-
rant further investigation in comprehensively identifying
the precise etiologic role of muscle in pressure-induced
deep tissue injury.
Conclusion
Our results demonstrated the elevation of ubiquitin,
MAFbx/atrogin-1, and 20S proteasome activity in the
presence of pathohistology in muscle following sustained
compression in an experimental deep pressure ulcer rat
model. The administration of the proteasome inhibitor
MG132 was effective in preventing the pathohistology,
increase in ubiquitin and MAFbx/atrogin-1, and increase
in 20S proteasome activity caused by compression. Our
results are consistent with the hypothesis that the mus-
cle ubiquitin proteasome system is involved in the
pathology of pressure-induced deep tissue injury. These
findings suggest that the ubiquitin proteasome system
could be a potential molecular target for exploring ther-
apeutic interventions to treat pressure-induced deep tis-
sue injury.
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